Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 9/20 | 0.68 |
| ▸ | CCR3 | P51677 | 2/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | TP53 | P04637 | 1/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.64 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6699777 | 0.98 | SIGMAR1 (0.67) | SIGMAR1CCR3MEN1TP53CYP1A2 | |
| SCHEMBL14389062 | 0.89 | ACHE (0.68) | SIGMAR1CCR3CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL5272251 | 0.84 | SLC6A2 (0.67) | SIGMAR1CCR3MEN1TP53CYP1A2 | |
| SCHEMBL17285905 | 0.83 | SIGMAR1 (0.97) | SIGMAR1CCR3MEN1TP53CYP1A2 | |
| SCHEMBL6701707 | 0.82 | SIGMAR1 (0.60) | SIGMAR1CCR3MEN1TP53CYP1A2 | |
| SCHEMBL7723966 | 0.81 | ACHE (0.61) | SIGMAR1CCR3 | |
| SCHEMBL6699058 | 0.81 | SIGMAR1 (0.63) | SIGMAR1CCR3MEN1TP53CYP1A2 | |
| SCHEMBL6700770 | 0.80 | SIGMAR1 (0.69) | SIGMAR1CCR3MEN1TP53CYP1A2 | |
| SCHEMBL22878315 | 0.80 | SIGMAR1 (0.69) | SIGMAR1CCR3MEN1TP53CYP1A2 | |
| SCHEMBL10438853 | 0.80 | SIGMAR1 (0.69) | SIGMAR1CCR3MEN1TP53CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040006081-A1 | Pharmaceutically active piperidine derivatives, in particular as modulators of chemokine receptor activity | ASTRAZENECA AB (SE) | 2004-01-08 | — | — | US | disclosed |
| EP-1289957-A1 | PHARMACEUTICALLY ACTIVE PIPERIDINE DERIVATIVES, IN PARTICULAR AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | AstraZeneca AB (SE) | 2003-03-12 | — | — | EP | disclosed |
| WO-2001087839-A1 | PHARMACEUTICALLY ACTIVE PIPERIDINE DERIVATIVES, IN PARTICULAR AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA AB (SE) | 2001-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006081-A1 | Pharmaceutically active piperidine derivatives, in particular as modulators of chemokine receptor activity | CCR5, CCR2, CCR1 | SIGMAR1 450/4885CCR3 8/4885MEN1 4785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.